Investment bank Ladenburg has named Robert “Bert” Hazlett as a managing director of equity research covering biopharmaceuticals. The appointment is effective immediately. Prior to joining Ladenburg, Hazlett worked at ROTH Capital Partners where he served as a senior research analyst covering the biotech and emerging pharmaceutical sectors.
MIAMI–(BUSINESS WIRE)–Ladenburg Thalmann Financial Services Inc. today announced that Robert “Bert” Hazlett, a senior equity analyst in the healthcare space, has been appointed as a Managing Director, Equity Research at Ladenburg Thalmann & Co. Inc. (“Ladenburg”) covering biopharmaceuticals, effective immediately. Mr. Hazlett will be based in Ladenburg’s New York City office.
With an 18-year tenure in the healthcare industry, Mr. Hazlett joins Ladenburg from ROTH Capital Partners where he covered the biotechnology and emerging pharmaceuticals sectors as a Senior Research Analyst. Previously, Mr. Hazlett served as a Managing Director and Senior Research Analyst at BMO Capital Markets focused on large-cap, emerging pharmaceutical and biotechnology research. Prior to that, Mr. Hazlett held various investment banking positions within Suntrust Robinson Humphrey, Robertson Stephens, Lehman Brothers and UBS Securities. Mr. Hazlett received his MBA from Columbia Business School and his Bachelor of Arts in Economics from Yale University.
David Rosenberg, Co-President and Chief Executive Officer of Ladenburg Thalmann & Co. Inc., said, “The addition of Bert to Ladenburg’s talented team further strengthens our presence in this important sector. Bert’s vast experience and wealth of expertise will be invaluable as we continue to grow and advance Ladenburg’s research, sales and trading capabilities.”
“Bert’s in-depth knowledge of the biotechnology and pharmaceutical industries makes him a great addition to Ladenburg, which has assisted healthcare clients in raising approximately $2 billion in over 55 transactions since 2012,” said Peter Blum, Co-President and Chief Executive Officer of Ladenburg Thalmann & Co. Inc. “With Bert as part of team, we are poised to continue our positive momentum and look forward to the contributions he will make to the firm and our expanding client base.”
Mr. Hazlett said, “Ladenburg is clearly committed to enhancing its already strong healthcare platform and I am excited about the opportunities ahead.
Ladenburg Thalmann Financial Services is engaged in independent brokerage and advisory services, investment banking, equity research, institutional sales and trading, and asset management services through its principal subsidiaries, Ladenburg Thalmann & Co. Inc., Investacorp, Inc., Triad Advisors, Inc. and Securities America, Inc., which together have approximately 2,800 financial advisors and approximately $90 billion in client assets. Founded in 1876 and a New York Stock Exchange member since 1879, Ladenburg Thalmann & Co. is a full service investment banking and brokerage firm providing services principally for middle market and emerging growth companies and high net worth individuals. Investacorp, Inc., a leading independent broker-dealer headquartered in Miami, Florida, has been serving the independent registered representative community since 1978. Founded in 1998, Triad Advisors, Inc. is a leading independent broker-dealer and registered investment advisor headquartered in Norcross, Georgia that offers a broad menu of products, services and total wealth management solutions. Securities America, based in Omaha, Nebraska, was founded in 1984 and is one of the largest and most successful independent broker-dealers in the country. Ladenburg Thalmann Financial Services is based in Miami, Florida. Ladenburg Thalmann & Co. is based in New York City, New York with regional offices in Miami, Naples and Boca Raton, Florida; Melville, New York; Boston, Massachusetts; Houston, Texas; and Calabasas, California. For more information, please visit www.ladenburg.com
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.